Growth Drivers
BioKangtai's 60 μg recombinant hepatitis B vaccine candidate works through a proposed relapse-prevention mechanism that could address a stated need in hepatitis B management, and clinical progress is the next observable development milestone. China's NMPA has approved the company to initiate a clinical trial of that candidate in patients who have achieved functional cure of chronic hepatitis B, aiming to prevent HBsAg relapse after treatment cessation.
The vaccine is designed to reinforce immune memory and to help sustain functional cure.
Risk Factors
A vaccine-quality investigation can interrupt use and demand, as occurred when use of the BioKangtai hepatitis B vaccine was temporarily suspended on December 20, 2013, pending an investigation into vaccine quality and production. China FDA's investigation then determined that the vaccine's properties and quality were within approved specifications and that it was produced using current Good Manufacturing Practices, which mitigates that exposure.
On January 17, 2014, Chinese authorities announced resumption of the use of the BioKangtai hepatitis B vaccine. The investigation showed that an allergic-shock case could have been caused by the vaccine, and the infant was treated successfully.
Product Overview
BioKangtai's work spans the research, production, and sale of human vaccines used for disease prevention, with eligibility and packaging that vary by vaccine. Its 13-valent pneumococcal conjugate vaccine is supplied in a single-dose pre-filled syringe containing 0.5 ml.
BioKangtai administers its rabies vaccine to people with rabies-virus exposure risk, including veterinarians, animal keepers, forestry practitioners, slaughterhouse workers, and rabies laboratory personnel.
